Sign In

Login

Password

Forgot Password ? Sign Up

Indolamin 2,3-dioxygenáza (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "Indolamin 2,3-dioxygenáza" in Czech language version.

refsWebsite
Global rank Czech rank
58doi.org
2nd place
4th place
30worldcat.org
5th place
3rd place
3nih.gov
4th place
8th place
2elsevier.com
610th place
203rd place
2nature.com
234th place
72nd place
1karger.com
4,489th place
2,098th place
1frontiersin.org
4,679th place
990th place
1future-science.com
low place
low place
1eurekaselect.com
low place
3,105th place
1aacrjournals.org
8,869th place
8,116th place

aacrjournals.org

cancerres.aacrjournals.org

  • HOU, De-Yan; MULLER, Alexander J.; SHARMA, Madhav D. Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research. 2007-01-15, roč. 67, čís. 2, s. 792–801. Dostupné online [cit. 2018-02-16]. doi:10.1158/0008-5472.can-06-2925. 

doi.org

doi.org

  • YAMAZAKI, F; KUROIWA, T; TAKIKAWA, O. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochemical Journal. 1985-09-15, roč. 230, čís. 3, s. 635–638. Dostupné online [cit. 2019-02-14]. ISSN 0264-6021. doi:10.1042/bj2300635. 
  • DAI, Wei; GUPTA, Sohan L. Molecular cloning, sequencing and expression of human interferon-γ-inducible indoleamine 2,3-dioxygenase cDNA. Biochemical and Biophysical Research Communications. Roč. 168, čís. 1, s. 1–8. Dostupné online [cit. 2018-02-16]. doi:10.1016/0006-291x(90)91666-g. 
  • NAJFELD, V.; MENNINGER, J.; MUHLEMAN, D. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12→p11 by fluorescent in situ hybridization. Cytogenetic and Genome Research. 1993, roč. 64, čís. 3–4, s. 231–232. Dostupné online [cit. 2018-02-16]. ISSN 1424-8581. doi:10.1159/000133584. (english) 
  • PRENDERGAST, George C.; METZ, Richard; MULLER, Alexander J. IDO2 in Immunomodulation and Autoimmune Disease. Frontiers in Immunology. 2014, roč. 5. Dostupné online [cit. 2018-02-16]. ISSN 1664-3224. doi:10.3389/fimmu.2014.00585. (English) 
  • BALL, Helen J.; SANCHEZ-PEREZ, Angeles; WEISER, Silvia. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007-07, roč. 396, čís. 1, s. 203–213. Dostupné online [cit. 2019-02-14]. ISSN 0378-1119. doi:10.1016/j.gene.2007.04.010. 
  • BADAWY, Abdulla A.-B.; BANO, Samina. Tryptophan Metabolism in Rat Liver after Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors. International Journal of Tryptophan Research. 2016-01, roč. 9, s. IJTR.S38190. Dostupné online [cit. 2019-02-14]. ISSN 1178-6469. doi:10.4137/ijtr.s38190. 
  • YOSHIDA, R.; HAYAISHI, O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide.. Proceedings of the National Academy of Sciences. 1978-08-01, roč. 75, čís. 8, s. 3998–4000. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.75.8.3998. 
  • YOSHIDA, R.; URADE, Y.; TOKUDA, M. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.. Proceedings of the National Academy of Sciences. 1979-08-01, roč. 76, čís. 8, s. 4084–4086. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.76.8.4084. 
  • UYTTENHOVE, Catherine; PILOTTE, Luc; THÉATE, Ivan. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 2003-09-21, roč. 9, čís. 10, s. 1269–1274. Dostupné online [cit. 2019-02-14]. ISSN 1078-8956. doi:10.1038/nm934. 
  • SHARMA, Madhav D.; BABAN, Babak; CHANDLER, Phillip. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. Journal of Clinical Investigation. 2007-09-04, roč. 117, čís. 9, s. 2570–2582. Dostupné online [cit. 2019-02-14]. ISSN 0021-9738. doi:10.1172/jci31911. 
  • QUINTANA, F. J.; MURUGAIYAN, G.; FAREZ, M. F. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences. 2010-11-10, roč. 107, čís. 48, s. 20768–20773. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.1009201107. 
  • MELLOR, Andrew L.; LEMOS, Henrique; HUANG, Lei. Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now?. Frontiers in Immunology. 2017-10-27, roč. 8. PMID 29163470 PMCID: PMC5663846. Dostupné online [cit. 2018-02-16]. ISSN 1664-3224. doi:10.3389/fimmu.2017.01360. PMID 29163470. 
  • MACKENZIE, Colin R.; HADDING, Ulrich; DÄUBENER, Walter. Interferon‐γ‐Induced Activation of Indoleamine 2,3‐Dioxygenase in Cord Blood Monocyte‐Derived Macrophages Inhibits the Growth of Group B Streptococci. The Journal of Infectious Diseases. 1998-09, roč. 178, čís. 3, s. 875–878. Dostupné online [cit. 2019-02-15]. ISSN 0022-1899. doi:10.1086/515347. 
  • ADAMS, O.; BESKEN, K.; OBERDORFER, C. Role of Indoleamine-2,3-Dioxygenase in Alpha/Beta and Gamma Interferon-Mediated Antiviral Effects against Herpes Simplex Virus Infections. Journal of Virology. 2004-02-12, roč. 78, čís. 5, s. 2632–2636. Dostupné online [cit. 2019-02-15]. ISSN 0022-538X. doi:10.1128/jvi.78.5.2632-2636.2004. 
  • OBOJES, K.; ANDRES, O.; KIM, K. S. Indoleamine 2,3-Dioxygenase Mediates Cell Type-Specific Anti-Measles Virus Activity of Gamma Interferon. Journal of Virology. 2005-05-26, roč. 79, čís. 12, s. 7768–7776. Dostupné online [cit. 2019-02-15]. ISSN 0022-538X. doi:10.1128/jvi.79.12.7768-7776.2005. 
  • ROMANI, Luigina; FALLARINO, Francesca; DE LUCA, Antonella. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature. 2008-01, roč. 451, čís. 7175, s. 211–215. Dostupné online [cit. 2019-02-15]. ISSN 0028-0836. doi:10.1038/nature06471. 
  • MOON, Yong Wha; HAJJAR, Joud; HWU, Patrick. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. Journal for Immunotherapy of Cancer. 2015-12-15, roč. 3. PMID 26674411 PMCID: PMC4678703. Dostupné online [cit. 2018-02-16]. ISSN 2051-1426. doi:10.1186/s40425-015-0094-9. PMID 26674411. 
  • CURTI, A.; TRABANELLI, S.; SALVESTRINI, V. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2008-11-20, roč. 113, čís. 11, s. 2394–2401. Dostupné online [cit. 2019-02-15]. ISSN 0006-4971. doi:10.1182/blood-2008-07-144485. 
  • HOLMGAARD, Rikke B.; ZAMARIN, Dmitriy; LI, Yanyun. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. 2015-10, roč. 13, čís. 2, s. 412–424. Dostupné online [cit. 2019-02-15]. ISSN 2211-1247. doi:10.1016/j.celrep.2015.08.077. 
  • MUNN, David H.; SHAFIZADEH, Ebrahim; ATTWOOD, John T. Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism. The Journal of Experimental Medicine. 1999-05-03, roč. 189, čís. 9, s. 1363–1372. Dostupné online [cit. 2019-02-15]. ISSN 0022-1007. doi:10.1084/jem.189.9.1363. 
  • FRUMENTO, Guido; ROTONDO, Rita; TONETTI, Michela. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase. The Journal of Experimental Medicine. 2002-08-12, roč. 196, čís. 4, s. 459–468. Dostupné online [cit. 2019-02-15]. ISSN 0022-1007. doi:10.1084/jem.20020121. 
  • OKAMOTO, Aikou; NIKAIDO, Takashi; OCHIAI, Kazunori. Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. International Congress Series. 2007-11, roč. 1304, s. 262–273. Dostupné online [cit. 2019-02-15]. ISSN 0531-5131. doi:10.1016/j.ics.2007.07.053. 
  • INABA, Tomoko; INO, Kazuhiko; KAJIYAMA, Hiroaki. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecologic Oncology. 2010-06, roč. 117, čís. 3, s. 423–428. Dostupné online [cit. 2019-02-15]. ISSN 0090-8258. doi:10.1016/j.ygyno.2010.02.028. 
  • UYTTENHOVE, Catherine; PILOTTE, Luc; THÉATE, Ivan. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 2003/10, roč. 9, čís. 10, s. 1269–1274. Dostupné online [cit. 2018-02-16]. ISSN 1546-170X. doi:10.1038/nm934. (En) 
  • JIANG, Tianze; SUN, Yingying; YIN, Zhichao. Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Medicinal Chemistry. 2015-02-16, roč. 7, čís. 2, s. 185–201. Dostupné online [cit. 2018-02-16]. doi:10.4155/fmc.14.151. (EN) 
  • MULLER, Alexander J; DUHADAWAY, James B; DONOVER, P Scott. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine. 2005/03, roč. 11, čís. 3, s. 312–319. Dostupné online [cit. 2018-02-16]. ISSN 1546-170X. doi:10.1038/nm1196. (En) 
  • LEE, Hwa Jung; JEONG, Young-Il; LEE, Tae-Hyung. Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Biochemical Pharmacology. Roč. 73, čís. 9, s. 1412–1421. Dostupné online [cit. 2018-02-16]. doi:10.1016/j.bcp.2006.12.018. 
  • CESARIO, A.; ROCCA, B.; RUTELLA, S. The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer. Current Medicinal Chemistry. 2011-05-01, roč. 18, čís. 15, s. 2263–2271. Dostupné online [cit. 2018-02-16]. doi:10.2174/092986711795656063. (anglicky) 
  • HOU, De-Yan; MULLER, Alexander J.; SHARMA, Madhav D. Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research. 2007-01-15, roč. 67, čís. 2, s. 792–801. Dostupné online [cit. 2018-02-16]. doi:10.1158/0008-5472.can-06-2925. 
  • HOU, D.-Y.; MULLER, A. J.; SHARMA, M. D. Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research. 2007-01-15, roč. 67, čís. 2, s. 792–801. Dostupné online [cit. 2019-02-15]. ISSN 0008-5472. doi:10.1158/0008-5472.can-06-2925. 
  • SOLIMAN, Hatem H.; JACKSON, Erica; NEUGER, Tony. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014-08-22, roč. 5, čís. 18. Dostupné online [cit. 2019-02-15]. ISSN 1949-2553. doi:10.18632/oncotarget.2357. 
  • BEATTY, Gregory L.; O'DWYER, Peter J.; CLARK, Jason. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 2017-01-04, roč. 23, čís. 13, s. 3269–3276. Dostupné online [cit. 2019-02-15]. ISSN 1078-0432. doi:10.1158/1078-0432.ccr-16-2272. 
  • BURRIS, Howard A.; GORDON, Michael S.; HELLMANN, Matthew David. A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 2017-05-20, roč. 35, čís. 15_suppl, s. 105–105. Dostupné online [cit. 2019-02-15]. ISSN 0732-183X. doi:10.1200/jco.2017.35.15_suppl.105. 
  • SIU, Lillian L.; GELMON, Karen; CHU, Quincy. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. Cancer Research. 2017-07-01, roč. 77, čís. 13 Supplement, s. CT116–CT116. Dostupné online [cit. 2019-02-15]. ISSN 0008-5472. doi:10.1158/1538-7445.am2017-ct116. 

dx.doi.org

  • YAMAZAKI, F; KUROIWA, T; TAKIKAWA, O. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochemical Journal. 1985-09-15, roč. 230, čís. 3, s. 635–638. Dostupné online [cit. 2019-02-14]. ISSN 0264-6021. doi:10.1042/bj2300635. 
  • YAMAMOTO, Shozo; HAYAISHI, Osamu. [53] Tryptophan 2,3-dioxygenase (tryptophan pyrrolase) (rabbit intestine). [s.l.]: Elsevier Dostupné online. ISBN 9780121818746. S. 434–438. 
  • BALL, Helen J.; SANCHEZ-PEREZ, Angeles; WEISER, Silvia. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007-07, roč. 396, čís. 1, s. 203–213. Dostupné online [cit. 2019-02-14]. ISSN 0378-1119. doi:10.1016/j.gene.2007.04.010. 
  • BADAWY, Abdulla A.-B.; BANO, Samina. Tryptophan Metabolism in Rat Liver after Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors. International Journal of Tryptophan Research. 2016-01, roč. 9, s. IJTR.S38190. Dostupné online [cit. 2019-02-14]. ISSN 1178-6469. doi:10.4137/ijtr.s38190. 
  • YOSHIDA, R.; HAYAISHI, O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide.. Proceedings of the National Academy of Sciences. 1978-08-01, roč. 75, čís. 8, s. 3998–4000. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.75.8.3998. 
  • YOSHIDA, R.; URADE, Y.; TOKUDA, M. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.. Proceedings of the National Academy of Sciences. 1979-08-01, roč. 76, čís. 8, s. 4084–4086. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.76.8.4084. 
  • UYTTENHOVE, Catherine; PILOTTE, Luc; THÉATE, Ivan. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 2003-09-21, roč. 9, čís. 10, s. 1269–1274. Dostupné online [cit. 2019-02-14]. ISSN 1078-8956. doi:10.1038/nm934. 
  • SHARMA, Madhav D.; BABAN, Babak; CHANDLER, Phillip. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. Journal of Clinical Investigation. 2007-09-04, roč. 117, čís. 9, s. 2570–2582. Dostupné online [cit. 2019-02-14]. ISSN 0021-9738. doi:10.1172/jci31911. 
  • QUINTANA, F. J.; MURUGAIYAN, G.; FAREZ, M. F. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences. 2010-11-10, roč. 107, čís. 48, s. 20768–20773. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.1009201107. 
  • MACKENZIE, Colin R.; HADDING, Ulrich; DÄUBENER, Walter. Interferon‐γ‐Induced Activation of Indoleamine 2,3‐Dioxygenase in Cord Blood Monocyte‐Derived Macrophages Inhibits the Growth of Group B Streptococci. The Journal of Infectious Diseases. 1998-09, roč. 178, čís. 3, s. 875–878. Dostupné online [cit. 2019-02-15]. ISSN 0022-1899. doi:10.1086/515347. 
  • ADAMS, O.; BESKEN, K.; OBERDORFER, C. Role of Indoleamine-2,3-Dioxygenase in Alpha/Beta and Gamma Interferon-Mediated Antiviral Effects against Herpes Simplex Virus Infections. Journal of Virology. 2004-02-12, roč. 78, čís. 5, s. 2632–2636. Dostupné online [cit. 2019-02-15]. ISSN 0022-538X. doi:10.1128/jvi.78.5.2632-2636.2004. 
  • OBOJES, K.; ANDRES, O.; KIM, K. S. Indoleamine 2,3-Dioxygenase Mediates Cell Type-Specific Anti-Measles Virus Activity of Gamma Interferon. Journal of Virology. 2005-05-26, roč. 79, čís. 12, s. 7768–7776. Dostupné online [cit. 2019-02-15]. ISSN 0022-538X. doi:10.1128/jvi.79.12.7768-7776.2005. 
  • ROMANI, Luigina; FALLARINO, Francesca; DE LUCA, Antonella. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature. 2008-01, roč. 451, čís. 7175, s. 211–215. Dostupné online [cit. 2019-02-15]. ISSN 0028-0836. doi:10.1038/nature06471. 
  • CURTI, A.; TRABANELLI, S.; SALVESTRINI, V. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2008-11-20, roč. 113, čís. 11, s. 2394–2401. Dostupné online [cit. 2019-02-15]. ISSN 0006-4971. doi:10.1182/blood-2008-07-144485. 
  • HOLMGAARD, Rikke B.; ZAMARIN, Dmitriy; LI, Yanyun. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. 2015-10, roč. 13, čís. 2, s. 412–424. Dostupné online [cit. 2019-02-15]. ISSN 2211-1247. doi:10.1016/j.celrep.2015.08.077. 
  • MUNN, David H.; SHAFIZADEH, Ebrahim; ATTWOOD, John T. Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism. The Journal of Experimental Medicine. 1999-05-03, roč. 189, čís. 9, s. 1363–1372. Dostupné online [cit. 2019-02-15]. ISSN 0022-1007. doi:10.1084/jem.189.9.1363. 
  • FRUMENTO, Guido; ROTONDO, Rita; TONETTI, Michela. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase. The Journal of Experimental Medicine. 2002-08-12, roč. 196, čís. 4, s. 459–468. Dostupné online [cit. 2019-02-15]. ISSN 0022-1007. doi:10.1084/jem.20020121. 
  • OKAMOTO, Aikou; NIKAIDO, Takashi; OCHIAI, Kazunori. Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. International Congress Series. 2007-11, roč. 1304, s. 262–273. Dostupné online [cit. 2019-02-15]. ISSN 0531-5131. doi:10.1016/j.ics.2007.07.053. 
  • INABA, Tomoko; INO, Kazuhiko; KAJIYAMA, Hiroaki. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecologic Oncology. 2010-06, roč. 117, čís. 3, s. 423–428. Dostupné online [cit. 2019-02-15]. ISSN 0090-8258. doi:10.1016/j.ygyno.2010.02.028. 
  • HOU, D.-Y.; MULLER, A. J.; SHARMA, M. D. Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research. 2007-01-15, roč. 67, čís. 2, s. 792–801. Dostupné online [cit. 2019-02-15]. ISSN 0008-5472. doi:10.1158/0008-5472.can-06-2925. 
  • SOLIMAN, Hatem H.; JACKSON, Erica; NEUGER, Tony. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014-08-22, roč. 5, čís. 18. Dostupné online [cit. 2019-02-15]. ISSN 1949-2553. doi:10.18632/oncotarget.2357. 
  • BEATTY, Gregory L.; O'DWYER, Peter J.; CLARK, Jason. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 2017-01-04, roč. 23, čís. 13, s. 3269–3276. Dostupné online [cit. 2019-02-15]. ISSN 1078-0432. doi:10.1158/1078-0432.ccr-16-2272. 
  • BURRIS, Howard A.; GORDON, Michael S.; HELLMANN, Matthew David. A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 2017-05-20, roč. 35, čís. 15_suppl, s. 105–105. Dostupné online [cit. 2019-02-15]. ISSN 0732-183X. doi:10.1200/jco.2017.35.15_suppl.105. 
  • SIU, Lillian L.; GELMON, Karen; CHU, Quincy. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. Cancer Research. 2017-07-01, roč. 77, čís. 13 Supplement, s. CT116–CT116. Dostupné online [cit. 2019-02-15]. ISSN 0008-5472. doi:10.1158/1538-7445.am2017-ct116. 

elsevier.com

linkinghub.elsevier.com

  • DAI, Wei; GUPTA, Sohan L. Molecular cloning, sequencing and expression of human interferon-γ-inducible indoleamine 2,3-dioxygenase cDNA. Biochemical and Biophysical Research Communications. Roč. 168, čís. 1, s. 1–8. Dostupné online [cit. 2018-02-16]. doi:10.1016/0006-291x(90)91666-g. 
  • LEE, Hwa Jung; JEONG, Young-Il; LEE, Tae-Hyung. Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells. Biochemical Pharmacology. Roč. 73, čís. 9, s. 1412–1421. Dostupné online [cit. 2018-02-16]. doi:10.1016/j.bcp.2006.12.018. 

eurekaselect.com

  • CESARIO, A.; ROCCA, B.; RUTELLA, S. The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer. Current Medicinal Chemistry. 2011-05-01, roč. 18, čís. 15, s. 2263–2271. Dostupné online [cit. 2018-02-16]. doi:10.2174/092986711795656063. (anglicky) 

frontiersin.org

journal.frontiersin.org

future-science.com

  • JIANG, Tianze; SUN, Yingying; YIN, Zhichao. Research progress of indoleamine 2,3-dioxygenase inhibitors. Future Medicinal Chemistry. 2015-02-16, roč. 7, čís. 2, s. 185–201. Dostupné online [cit. 2018-02-16]. doi:10.4155/fmc.14.151. (EN) 

karger.com

  • NAJFELD, V.; MENNINGER, J.; MUHLEMAN, D. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12→p11 by fluorescent in situ hybridization. Cytogenetic and Genome Research. 1993, roč. 64, čís. 3–4, s. 231–232. Dostupné online [cit. 2018-02-16]. ISSN 1424-8581. doi:10.1159/000133584. (english) 

nature.com

  • UYTTENHOVE, Catherine; PILOTTE, Luc; THÉATE, Ivan. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 2003/10, roč. 9, čís. 10, s. 1269–1274. Dostupné online [cit. 2018-02-16]. ISSN 1546-170X. doi:10.1038/nm934. (En) 
  • MULLER, Alexander J; DUHADAWAY, James B; DONOVER, P Scott. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine. 2005/03, roč. 11, čís. 3, s. 312–319. Dostupné online [cit. 2018-02-16]. ISSN 1546-170X. doi:10.1038/nm1196. (En) 

nih.gov

ncbi.nlm.nih.gov

worldcat.org

  • YAMAZAKI, F; KUROIWA, T; TAKIKAWA, O. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochemical Journal. 1985-09-15, roč. 230, čís. 3, s. 635–638. Dostupné online [cit. 2019-02-14]. ISSN 0264-6021. doi:10.1042/bj2300635. 
  • NAJFELD, V.; MENNINGER, J.; MUHLEMAN, D. Localization of indoleamine 2,3-dioxygenase gene (INDO) to chromosome 8p12→p11 by fluorescent in situ hybridization. Cytogenetic and Genome Research. 1993, roč. 64, čís. 3–4, s. 231–232. Dostupné online [cit. 2018-02-16]. ISSN 1424-8581. doi:10.1159/000133584. (english) 
  • PRENDERGAST, George C.; METZ, Richard; MULLER, Alexander J. IDO2 in Immunomodulation and Autoimmune Disease. Frontiers in Immunology. 2014, roč. 5. Dostupné online [cit. 2018-02-16]. ISSN 1664-3224. doi:10.3389/fimmu.2014.00585. (English) 
  • BALL, Helen J.; SANCHEZ-PEREZ, Angeles; WEISER, Silvia. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007-07, roč. 396, čís. 1, s. 203–213. Dostupné online [cit. 2019-02-14]. ISSN 0378-1119. doi:10.1016/j.gene.2007.04.010. 
  • BADAWY, Abdulla A.-B.; BANO, Samina. Tryptophan Metabolism in Rat Liver after Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors. International Journal of Tryptophan Research. 2016-01, roč. 9, s. IJTR.S38190. Dostupné online [cit. 2019-02-14]. ISSN 1178-6469. doi:10.4137/ijtr.s38190. 
  • YOSHIDA, R.; HAYAISHI, O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide.. Proceedings of the National Academy of Sciences. 1978-08-01, roč. 75, čís. 8, s. 3998–4000. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.75.8.3998. 
  • YOSHIDA, R.; URADE, Y.; TOKUDA, M. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.. Proceedings of the National Academy of Sciences. 1979-08-01, roč. 76, čís. 8, s. 4084–4086. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.76.8.4084. 
  • UYTTENHOVE, Catherine; PILOTTE, Luc; THÉATE, Ivan. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 2003-09-21, roč. 9, čís. 10, s. 1269–1274. Dostupné online [cit. 2019-02-14]. ISSN 1078-8956. doi:10.1038/nm934. 
  • SHARMA, Madhav D.; BABAN, Babak; CHANDLER, Phillip. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. Journal of Clinical Investigation. 2007-09-04, roč. 117, čís. 9, s. 2570–2582. Dostupné online [cit. 2019-02-14]. ISSN 0021-9738. doi:10.1172/jci31911. 
  • QUINTANA, F. J.; MURUGAIYAN, G.; FAREZ, M. F. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences. 2010-11-10, roč. 107, čís. 48, s. 20768–20773. Dostupné online [cit. 2019-02-14]. ISSN 0027-8424. doi:10.1073/pnas.1009201107. 
  • MELLOR, Andrew L.; LEMOS, Henrique; HUANG, Lei. Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now?. Frontiers in Immunology. 2017-10-27, roč. 8. PMID 29163470 PMCID: PMC5663846. Dostupné online [cit. 2018-02-16]. ISSN 1664-3224. doi:10.3389/fimmu.2017.01360. PMID 29163470. 
  • MACKENZIE, Colin R.; HADDING, Ulrich; DÄUBENER, Walter. Interferon‐γ‐Induced Activation of Indoleamine 2,3‐Dioxygenase in Cord Blood Monocyte‐Derived Macrophages Inhibits the Growth of Group B Streptococci. The Journal of Infectious Diseases. 1998-09, roč. 178, čís. 3, s. 875–878. Dostupné online [cit. 2019-02-15]. ISSN 0022-1899. doi:10.1086/515347. 
  • ADAMS, O.; BESKEN, K.; OBERDORFER, C. Role of Indoleamine-2,3-Dioxygenase in Alpha/Beta and Gamma Interferon-Mediated Antiviral Effects against Herpes Simplex Virus Infections. Journal of Virology. 2004-02-12, roč. 78, čís. 5, s. 2632–2636. Dostupné online [cit. 2019-02-15]. ISSN 0022-538X. doi:10.1128/jvi.78.5.2632-2636.2004. 
  • OBOJES, K.; ANDRES, O.; KIM, K. S. Indoleamine 2,3-Dioxygenase Mediates Cell Type-Specific Anti-Measles Virus Activity of Gamma Interferon. Journal of Virology. 2005-05-26, roč. 79, čís. 12, s. 7768–7776. Dostupné online [cit. 2019-02-15]. ISSN 0022-538X. doi:10.1128/jvi.79.12.7768-7776.2005. 
  • ROMANI, Luigina; FALLARINO, Francesca; DE LUCA, Antonella. Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. Nature. 2008-01, roč. 451, čís. 7175, s. 211–215. Dostupné online [cit. 2019-02-15]. ISSN 0028-0836. doi:10.1038/nature06471. 
  • MOON, Yong Wha; HAJJAR, Joud; HWU, Patrick. Targeting the indoleamine 2,3-dioxygenase pathway in cancer. Journal for Immunotherapy of Cancer. 2015-12-15, roč. 3. PMID 26674411 PMCID: PMC4678703. Dostupné online [cit. 2018-02-16]. ISSN 2051-1426. doi:10.1186/s40425-015-0094-9. PMID 26674411. 
  • CURTI, A.; TRABANELLI, S.; SALVESTRINI, V. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2008-11-20, roč. 113, čís. 11, s. 2394–2401. Dostupné online [cit. 2019-02-15]. ISSN 0006-4971. doi:10.1182/blood-2008-07-144485. 
  • HOLMGAARD, Rikke B.; ZAMARIN, Dmitriy; LI, Yanyun. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. 2015-10, roč. 13, čís. 2, s. 412–424. Dostupné online [cit. 2019-02-15]. ISSN 2211-1247. doi:10.1016/j.celrep.2015.08.077. 
  • MUNN, David H.; SHAFIZADEH, Ebrahim; ATTWOOD, John T. Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism. The Journal of Experimental Medicine. 1999-05-03, roč. 189, čís. 9, s. 1363–1372. Dostupné online [cit. 2019-02-15]. ISSN 0022-1007. doi:10.1084/jem.189.9.1363. 
  • FRUMENTO, Guido; ROTONDO, Rita; TONETTI, Michela. Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase. The Journal of Experimental Medicine. 2002-08-12, roč. 196, čís. 4, s. 459–468. Dostupné online [cit. 2019-02-15]. ISSN 0022-1007. doi:10.1084/jem.20020121. 
  • OKAMOTO, Aikou; NIKAIDO, Takashi; OCHIAI, Kazunori. Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. International Congress Series. 2007-11, roč. 1304, s. 262–273. Dostupné online [cit. 2019-02-15]. ISSN 0531-5131. doi:10.1016/j.ics.2007.07.053. 
  • INABA, Tomoko; INO, Kazuhiko; KAJIYAMA, Hiroaki. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecologic Oncology. 2010-06, roč. 117, čís. 3, s. 423–428. Dostupné online [cit. 2019-02-15]. ISSN 0090-8258. doi:10.1016/j.ygyno.2010.02.028. 
  • UYTTENHOVE, Catherine; PILOTTE, Luc; THÉATE, Ivan. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine. 2003/10, roč. 9, čís. 10, s. 1269–1274. Dostupné online [cit. 2018-02-16]. ISSN 1546-170X. doi:10.1038/nm934. (En) 
  • MULLER, Alexander J; DUHADAWAY, James B; DONOVER, P Scott. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nature Medicine. 2005/03, roč. 11, čís. 3, s. 312–319. Dostupné online [cit. 2018-02-16]. ISSN 1546-170X. doi:10.1038/nm1196. (En) 
  • CHIARUGI, A.; DELLO SBARBA, P.; PACCAGNINI, A. Combined inhibition of indoleamine 2,3-dioxygenase and nitric oxide synthase modulates neurotoxin release by interferon-gamma-activated macrophages. Journal of Leukocyte Biology. August 2000, roč. 68, čís. 2, s. 260–266. PMID 10947071. Dostupné online [cit. 2018-02-16]. ISSN 0741-5400. PMID 10947071. 
  • HOU, D.-Y.; MULLER, A. J.; SHARMA, M. D. Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses. Cancer Research. 2007-01-15, roč. 67, čís. 2, s. 792–801. Dostupné online [cit. 2019-02-15]. ISSN 0008-5472. doi:10.1158/0008-5472.can-06-2925. 
  • SOLIMAN, Hatem H.; JACKSON, Erica; NEUGER, Tony. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget. 2014-08-22, roč. 5, čís. 18. Dostupné online [cit. 2019-02-15]. ISSN 1949-2553. doi:10.18632/oncotarget.2357. 
  • BEATTY, Gregory L.; O'DWYER, Peter J.; CLARK, Jason. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clinical Cancer Research. 2017-01-04, roč. 23, čís. 13, s. 3269–3276. Dostupné online [cit. 2019-02-15]. ISSN 1078-0432. doi:10.1158/1078-0432.ccr-16-2272. 
  • BURRIS, Howard A.; GORDON, Michael S.; HELLMANN, Matthew David. A phase Ib dose escalation study of combined inhibition of IDO1 (GDC-0919) and PD-L1 (atezolizumab) in patients (pts) with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology. 2017-05-20, roč. 35, čís. 15_suppl, s. 105–105. Dostupné online [cit. 2019-02-15]. ISSN 0732-183X. doi:10.1200/jco.2017.35.15_suppl.105. 
  • SIU, Lillian L.; GELMON, Karen; CHU, Quincy. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. Cancer Research. 2017-07-01, roč. 77, čís. 13 Supplement, s. CT116–CT116. Dostupné online [cit. 2019-02-15]. ISSN 0008-5472. doi:10.1158/1538-7445.am2017-ct116.